Concord Healthcare Announces Official Release of the Proton Therapy Large Model

Rhea-AI Summary

Concord Healthcare Group (NYSE: CCM), a subsidiary of Concord Medical Services Holdings, has officially launched China's first large language model (LLM) specialized in proton therapy. The model has been successfully deployed at Guangzhou Concord Cancer Hospital, where it has already demonstrated success in multiple patient treatment cases.

The LLM integrates nearly 10,000 high-quality radiotherapy cases, incorporating multimodal medical data, Proton China data, and professional journal literature. The technology has shown promising results with precise treatment capabilities, significant efficacy, and reduced side effects. This development builds on Concord Healthcare's extensive experience in tumor diagnosis and treatment technology.

Positive

• First proton therapy LLM in China, establishing technological leadership
• Successfully deployed and validated with multiple patient cases
• Integration of 10,000 high-quality radiotherapy cases enhancing model accuracy
• Demonstrated positive clinical outcomes with reduced side effects

Negative

• None.

News Market Reaction – CCM

-0.27%

1 alert

-0.27% News Effect

On the day this news was published, CCM declined 0.27%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEIJING, May 29, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology. Concord Healthcare's self-developed large language model ("LLM") in the vertical field of proton therapy was officially released and successfully deployed in Guangzhou Concord Cancer Hospital. Since the commencement of the proton therapy in Guangzhou Concord Cancer Hospital, the proton therapy has completed a number of high-quality patient treatment cases, demonstrating the outstanding advantages of precise treatment, significant efficacy, and reduced side effects.

Concord Healthcare's proton LLM is the first LLM focusing on proton therapy in China, and its research and development relies on the tumor diagnosis and treatment technology system and massive data accumulated by Concord Healthcare over the years. It integrates nearly 10,000 high-quality radiotherapy cases to construct multimodal medical data, and also integrates data from Proton China and professional journal literature to achieve enhancement of model training.

The Company previously announced the listing of Concord Healthcare's H shares on the HKSE on January 9, 2024. The information related to Concord Healthcare's Transactions on the HKSE is accessible through the HKSE's website at www.hkexnews.hk.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.

About Concord Healthcare

Concord Healthcare is an oncology healthcare provider in China. Concord Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions through medical equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists and diagnosis and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related services, Concord Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related services, including primarily sales and installing of medical equipment and software, management and technical support, and operating lease.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

View original content:https://www.prnewswire.com/news-releases/concord-healthcare-announces-official-release-of-the-proton-therapy-large-model-302468669.html

SOURCE Concord Medical Services Holdings Limited

FAQ

What is the new proton therapy LLM launched by Concord Healthcare (NYSE: CCM)?

Concord Healthcare has launched China's first large language model specialized in proton therapy, integrating 10,000 radiotherapy cases, Proton China data, and professional literature for enhanced tumor diagnosis and treatment.

Where has Concord Healthcare (CCM) deployed its new proton therapy LLM?

The proton therapy LLM has been deployed at Guangzhou Concord Cancer Hospital, where it has already completed multiple successful patient treatment cases.

What are the main benefits of Concord Healthcare's proton therapy LLM?

The main benefits include precise treatment capabilities, significant efficacy in treating tumors, and reduced side effects for patients.

How many radiotherapy cases does Concord Healthcare's proton LLM integrate?

The LLM integrates nearly 10,000 high-quality radiotherapy cases to construct multimodal medical data, along with additional data from Proton China and professional journal literature.